HIV infection and comorbidities;Comorbidités chez le patient infecté par le VIH

Revue du Praticien

Volumn 56, Issue 9, 2006, Pages 995-1004

  Lacombe, Karine ^b   Pacanowski, Jérôme ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CANCER; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC HEPATITIS; COMORBIDITY; FRANCE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MORTALITY; OPPORTUNISTIC INFECTION; PREVALENCE; REVIEW; SCREENING TEST; SUICIDE;

COMORBIDITY; HEPATITIS, CHRONIC; HIV INFECTIONS; HUMANS; NEOPLASMS; SUICIDE;

EID: 33646877679     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005;34:121-30.
2. Bonnet F, Lewden C, May T, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 2004;101:317-24
3. Launay O, Guillevin L. Epidemiology of HIV-associated malignancies. Bull Cancer 2003;90:387-92.
4. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-44.
5. Herlda M, Mary-Krause M, Kaphan R, et al. Incidence of Non-AIDS-Defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003;21:3447-53.
6. Spano J, Atlan D, Breau J, Farge D. AIDS and non-AIDS-related malignancies: a new vexing challenge in HIV-positive patients. Part II. Cervical and anal squamous epithelial lesions, lung cancer, testicular germ cell cancers, and skin cancers. Eur J Intern Med 2002;13:227-32.
7. Frisch M, Biggar RJ, Engels EA, Goedert JJ, for the AIDS-Cancer Match Registry Study Group. Association of Cancer With AIDS-Related Immunosuppression in Adults. JAMA 2001;285:1736-45.
8. Grulich AE, Li Y, McDonald A, Correll PKL Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002;16:1155-61.
9. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005;97:425-32.
10. Spano J, Faivre S. Non-AIDS-related malignancies: prognostic and treatment. Bull Cancer 2003;90:413-8.
11. Spano J, Massiani M, Bentata M, et al. Lung cancer in patients with HIV Infection and review of the literature. Med Oncol 2004;21:109-15.
12. Stall R, Greenwood G, Acree M, Paul J, Coates T. Cigarette smoking among gay and bisexual men. Am J Public Health 1999;89:1875-8.
13. Ortholan C, Francois E, Gerard J. Lésions préné oplasiques et cancer du canal anal. Bull Cancer 2003;90:405-11.
14. Krentz H, Kliewer G, Gill M. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Medicine 2005;6:99-106.
15. Heckman T, Miller J, Kochman A, Kalichman S, Carlson B, Silverthorn M. Thoughts of suicide among HIV-infected rural persons enrolled in a telephone-delivered mental health intervention. Ann Behav Med 2002;24:141-8.
16. Haller DL, Miles DR. Suicidal ideation among psychiatric patients with HIV: psychiatric morbidity and quality of life. AIDS Behav 2003;7:101-8.
17. Komiti A, Judd F, Grech P, et al. Suicidal behaviour in people with HIV/AIDS: a review. Aust N Z J Psychiatry 2001;35:747-57.
18. Larsen C, Pialoux G, Salmon D, et al. Prévalence des hépatites B et C dans la population VIH+, France, juin 2004. BEH 2005;23:109-12.
19. InVS. Estimation des taux de prévalence des anticorps anti-VHC et des marqueurs du virus de l'hépatite B chez les assurés sociaux du régime générale de France métropolitaine, 2003-2004. Paris: InVS, 2005.
20. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-6.
21. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002;16:1663-71.
22. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2000;44:3451-5.
23. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999;30:1054-8.
24. Gilson RJC, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997;11:597-606.
25. Vogel M, Bieniek B, Jessen H, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat 2005;12:207-11.
26. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard Interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004;292:2839-48
27. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-infected Patients. N Engl J Med 2004;351:438-50.
28. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6.